Breaking News

AstraZeneca to Pay $700 MN for Cancer Drug

Medimmune enters into strategic cancer vaccine collaboration and license agreement with Inovio Pharmaceuticals

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca, through MedImmune, its global biologics research and development arm, has entered into a license agreement and collaboration with Inovio Pharmaceuticals, a biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases. MedImmune will acquire exclusive rights to Inovio’s INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. INO-3112, which is in phase I/II clinical trials for cervical and head and neck c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters